111 related articles for article (PubMed ID: 38457819)
21. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
[TBL] [Abstract][Full Text] [Related]
22. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
[TBL] [Abstract][Full Text] [Related]
23. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV.
Johnston SS; Juday T; Seekins D; Espindle D; Chu BC
J Manag Care Pharm; 2012 Mar; 18(2):129-45. PubMed ID: 22380472
[TBL] [Abstract][Full Text] [Related]
24. Out-of-Pocket Payment for Ambulatory Blood Pressure Monitoring Among Commercially Insured in the United States.
Desai R; Dietrich EA; Park H; Smith SM
Am J Hypertens; 2020 Nov; 33(11):999-1002. PubMed ID: 32930343
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
26. Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer.
McDermott CL; Curtis JR; Sun Q; Fedorenko C; Kreizenbeck K; Ramsey SD
J Oncol Pharm Pract; 2022 Jun; 28(4):836-841. PubMed ID: 33823685
[TBL] [Abstract][Full Text] [Related]
27. Physician Participation in Medicare Accountable Care Organizations and Spillovers in Commercial Spending.
Post B; Ryan AM; Moloci NM; Li J; Dupree JM; Hollingsworth JM
Med Care; 2019 Apr; 57(4):305-311. PubMed ID: 30789539
[TBL] [Abstract][Full Text] [Related]
28. Specialty drug and health care utilization vary by wage level in employer-sponsored health plans.
Sherman BW; Sils B; Kamin L; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):918-928. PubMed ID: 35722830
[No Abstract] [Full Text] [Related]
29. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
30. The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
Goldsberry WN; Summerlin SS; Guyton A; Caddell B; Huh WK; Kim KH; Liang MI
Gynecol Oncol; 2021 Mar; 160(3):800-804. PubMed ID: 33414026
[TBL] [Abstract][Full Text] [Related]
31. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
32. Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020.
Chua KP; Conti RM; Becker NV
JAMA Netw Open; 2021 Oct; 4(10):e2129894. PubMed ID: 34661662
[TBL] [Abstract][Full Text] [Related]
33. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
Mouslim MC; Trujillo AJ; Alexander GC; Segal JB
Value Health; 2020 Dec; 23(12):1599-1605. PubMed ID: 33248515
[TBL] [Abstract][Full Text] [Related]
34. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
35. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.
Gilman BH; Kautter J
Health Serv Res; 2008 Apr; 43(2):478-95. PubMed ID: 18370964
[TBL] [Abstract][Full Text] [Related]
36. Does a One-Size-Fits-All Cost-Sharing Approach Incentivize Appropriate Medication Use? A Roundtable on the Fairness and Ethics Associated with Variable Cost Sharing.
Graff JS; Shih C; Barker T; Dieguez G; Larson C; Sherman H; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6):621-627. PubMed ID: 28530519
[TBL] [Abstract][Full Text] [Related]
37. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
38. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
39. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China.
Yong M; Xianjun X; Jinghu L; Yunyun F
Aust Health Rev; 2018 Feb; 42(1):39-44. PubMed ID: 28263706
[TBL] [Abstract][Full Text] [Related]
40. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.
Faridi KF; Dayoub EJ; Ross JS; Dhruva SS; Ahmad T; Desai NR
J Am Coll Cardiol; 2022 Jun; 79(25):2516-2525. PubMed ID: 35738713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
